About this trial
Capacitation in vitro maturation (CAPA-IVM) has improved oocyte maturation and resulted in live births. Because cumulus cells (CCs) communicate bidirectionally with the oocyte, their transcriptomic profile may serve as a non-invasive biomarker of oocyte and embryo competence. This prospective pilot study will analyze CCs gene expression after CAPA-IVM using RNA sequencing and pathway analysis, and correlate findings with embryological outcomes including fertilization, day-3 cleavage, and blastocyst formation. Results are expected to provide insights into the molecular basis of oocyte competence and support development of non-invasive embryo selection strategies.
Eligibility criteria
Qualifiers
Women 18-38 years
BMI =< 32kg/m2
Diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam 2003 criteria, meet at least 2 of the following 3 features: (1) Oligo-ovulation or anovulation. (2) Clinical and/or biochemical signs of hyperandrogenism (3) Polycystic ovarian morphology on ultrasound.
Indicated for CAPA-IVM treatment.
Disqualifiers
Retrieved sperm from surgical procedures
Previous IVF cycle with total immature oocytes
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Mỹ Đức Hospital
Lead sponsor
Vrije Universiteit Brussel
Collaborator